foxo4-dri vs gdf-11 Deficiency of Accelerates TAC-Induced Heart Failure by Impairing Cardiac Angiogenesis FOXO4-DRI induces keloid senescent fibroblast

The $8 billion reinvestment will be allocated in the following ways: $500 Million for the Interim Access Assurance Fund - temporary, time limited funding to ensure current trusted and viable Medicaid safety net providers can fully participate in the DSRIP transformation without unproductive disruption $6.42 Billion for Delivery System Reform Incentive Payments (DSRIP) - including DSRIP Planning Grants, DSRIP Provider Incentive Payments, and DSRIP Administrative costs $1.08 Billion for other Medicaid Redesign purposes - this funding will support Health Home Development through a State Plan Amendment, and investments in long term care workforce and enhanced behavioral health services through managed care contract payments A2

Because human safety data are still limited and BPC-157 is not FDA-approved, patient selection matters

Novo shared the latest data from the Phase III REDEFINE 2 trial evaluating the drug in overweight or obese patients with type 2 diabetes

1989;13:S77S88